Literature DB >> 14622351

Pathogenesis of diabetic retinopathy and the renin-angiotensin system.

Hideharu Funatsu1, Hidetoshi Yamashita.   

Abstract

Despite the beneficial effects of good glycaemic control, loss of vision because of diabetic retinopathy (DR) still occurs. Recent studies have suggested that hypertension is a risk factor for the development and progression of DR and that blood pressure reduction can delay the progression of retinopathy. The renin-angiotensin system is activated by chronic hyperglycaemia, and the vitreous fluid level of angiotensin II (AII) is elevated in patients with proliferative diabetic retinopathy and diabetic macular oedema. AII increases vascular permeability and promotes neovascularization. It has been suggested that an autocrine-paracrine relationship may exist between AII and vascular endothelial growth factor in the ocular tissues. Accordingly, angiotensin-converting enzyme inhibitors or AII Type 1 (AT1) receptor blockers may be useful therapeutic agents for preventing the progression of DR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14622351     DOI: 10.1046/j.1475-1313.2003.00134.x

Source DB:  PubMed          Journal:  Ophthalmic Physiol Opt        ISSN: 0275-5408            Impact factor:   3.117


  12 in total

1.  Serum prorenin levels and diabetic retinopathy in type 2 diabetes: new method to measure serum level of prorenin using antibody activating direct kinetic assay.

Authors:  H Yokota; F Mori; K Kai; T Nagaoka; N Izumi; A Takahashi; T Hikichi; A Yoshida; F Suzuki; Y Ishida
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

Review 2.  Unraveling the role of genetics in the pathogenesis of diabetic retinopathy.

Authors:  Ashok Sharma; Maria L Valle; Connor Beveridge; Yutao Liu; Shruti Sharma
Journal:  Eye (Lond)       Date:  2019-01-24       Impact factor: 3.775

3.  Current concepts in intravitreal drug therapy for diabetic retinopathy.

Authors:  Anant Pai; Maha M El Shafei; Osman A Z Mohammed; Mustafa Al Hashimi
Journal:  Saudi J Ophthalmol       Date:  2010-06-30

Review 4.  Iron overload in diabetic retinopathy: a cause or a consequence of impaired mechanisms?

Authors:  Andreea Ciudin; Cristina Hernández; Rafael Simó
Journal:  Exp Diabetes Res       Date:  2010-08-08

5.  Interruption of Wnt signaling in Müller cells ameliorates ischemia-induced retinal neovascularization.

Authors:  Kelu Kevin Zhou; Siribhinya Benyajati; Yun Le; Rui Cheng; Wenbo Zhang; Jian-xing Ma
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

Review 6.  Therapeutic targets of renin-angiotensin system in ocular disorders.

Authors:  Rajesh Choudhary; Mandeep Singh Kapoor; Amrita Singh; Surendra H Bodakhe
Journal:  J Curr Ophthalmol       Date:  2016-10-20

7.  Retinal angiotensin II and angiotensin-(1-7) response to hyperglycemia and an intervention with captopril.

Authors:  Preenie deS Senanayake; Vera L Bonilha; John W Peterson; Yoshiro Yamada; Sadashiva S Karnik; Firouz Daneshgari; K Bridget Brosnihan; Joe G Hollyfield
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Jul-Sep       Impact factor: 1.636

8.  A systematic meta-analysis of genetic association studies for diabetic retinopathy.

Authors:  Sotoodeh Abhary; Alex W Hewitt; Kathryn P Burdon; Jamie E Craig
Journal:  Diabetes       Date:  2009-07-08       Impact factor: 9.461

9.  The therapeutic effects of angiotensin-converting enzyme inhibitors in severe non-proliferative diabetic retinopathy.

Authors:  Yong Jae Cha; Sung Jin Kim
Journal:  Korean J Ophthalmol       Date:  2007-03

10.  Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina.

Authors:  Toshihide Kurihara; Yoko Ozawa; Norihiro Nagai; Kei Shinoda; Kousuke Noda; Yutaka Imamura; Kazuo Tsubota; Hideyuki Okano; Yuichi Oike; Susumu Ishida
Journal:  Diabetes       Date:  2008-05-16       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.